Expression of Zinc Finger E-box-binding Homeobox Factor 1 in Epithelial Ovarian Cancer: A Clinicopathological Analysis of 238 Patients

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2016 Feb 13

PMID 26870350

Citations 6

Authors

Xiufang Li

Ruixia Huang

Ruth Holm Li

Claes G Trope

Jahn M Nesland

Zhenhe Suo

Affiliations

Soon will be listed here.

Abstract

A growing body of evidence indicates that aberrant activation of epithelial-to-mesenchymal transition (EMT) plays a key role in tumor cell invasion and metastasis. Zinc finger E-box-binding homeobox factor 1 (ZEB1), as a crucial mediator of EMT, contributes to the malignant progression of various epithelial tumors. To determine whether ZEB1 is involved in the progression of ovarian cancer, we immunohistochemically evaluated the expression of ZEB1 in 238 cases of epithelial ovarian cancer (EOC) and analyzed its associations with clinicopathological parameters. Positive expression of ZEB1 was observed in 32.8% (78/238) of EOCs and it was found to be significantly associated with advanced tumor stage (P=0.001). The survival analysis indicated that the expression of ZEB1 was associated with a poor 5-year progression-free survival (PFS) (P=0.021). A similar tendency was also observed between the expression of ZEB1 and 5-year overall survival, although it did not reach statistical significance (P=0.118). Moreover, the multivariate analysis demonstrated that ZEB1 expression was an independent risk factor for 5-year PFS in ovarian cancer. Taken together, our data provide evidence that ZEB1 may play a crucial role in promoting aggressive ovarian carcinoma progression. Therefore, ZEB1 may serve as an effectively predictive marker and a potential target for therapeutic intervention in EOC.

Citing Articles

Clinicopathologic Impact of NANOG, ZEB1, and EpCAM Biomarkers on Prognosis of Serous Ovarian Carcinoma.

Ibrahim H, Abdelrahman A, Elsebai E, Gharieb S, Fahmy M, Ramadan M Asian Pac J Cancer Prev. 2023; 24(9):3247-3259.

PMID: 37774079 PMC: 10762767. DOI: 10.31557/APJCP.2023.24.9.3247.

The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.

Rae S, Spillane C, Blackshields G, Madden S, Keenan J, Stordal B Hum Cell. 2022; 35(5):1547-1559.

PMID: 35794446 PMC: 9374625. DOI: 10.1007/s13577-022-00744-y.

Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer.

Sestito R, Cianfrocca R, Tocci P, Rosano L, Sacconi A, Blandino G Commun Biol. 2020; 3(1):677.

PMID: 33188287 PMC: 7666224. DOI: 10.1038/s42003-020-01404-3.

MicroRNA-342 Prohibits Proliferation and Invasion of Melanoma Cells by Directly Targeting Zinc-Finger E-Box-Binding Homeobox 1.

Shi Q, He Q, Wei J Oncol Res. 2018; 26(9):1447-1455.

PMID: 29495972 PMC: 7844687. DOI: 10.3727/096504018X15193823766141.

Autophagy inhibition promotes epithelial-mesenchymal transition through ROS/HO-1 pathway in ovarian cancer cells.

Zhao Z, Zhao J, Xue J, Zhao X, Liu P Am J Cancer Res. 2016; 6(10):2162-2177.

PMID: 27822409 PMC: 5088283.

References

Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M . The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007; 26(49):6979-88. PMC: 2899859. DOI: 10.1038/sj.onc.1210508. View

Davidson B, Holth A, Hellesylt E, Tan T, Huang R, Trope C . The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Hum Pathol. 2014; 46(1):1-8. DOI: 10.1016/j.humpath.2014.10.004. View

Huang R, Ma Y, Holm R, Trope C, Nesland J, Suo Z . Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations. PLoS One. 2014; 8(12):e83238. PMC: 3873286. DOI: 10.1371/journal.pone.0083238. View

Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007; 7(6):415-28. DOI: 10.1038/nrc2131. View

Li P, Wang J, Chu M, Zhang K, Yang R, Gao W . Zeb1 promotes androgen independence of prostate cancer via induction of stem cell-like properties. Exp Biol Med (Maywood). 2014; 239(7):813-822. DOI: 10.1177/1535370214538727. View

Jia B, Liu H, Kong Q, Li B . Overexpression of ZEB1 associated with metastasis and invasion in patients with gastric carcinoma. Mol Cell Biochem. 2012; 366(1-2):223-9. DOI: 10.1007/s11010-012-1299-6. View

Harada K, Miyake H, Kusuda Y, Fujisawa M . Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int. 2012; 110(11 Pt C):E1131-7. DOI: 10.1111/j.1464-410X.2012.11297.x. View

Hurt E, Saykally J, Anose B, Kalli K, Sanders M . Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem. 2008; 318(1-2):89-99. DOI: 10.1007/s11010-008-9860-z. View

Dutta D, Dutta I . Origin of ovarian cancer: molecular profiling. J Obstet Gynaecol India. 2014; 63(3):152-7. PMC: 3696134. DOI: 10.1007/s13224-013-0419-x. View

10.

Miyahara S, Hamasaki M, Hamatake D, Yamashita S, Shiraishi T, Iwasaki A . Clinicopathological analysis of pleomorphic carcinoma of the lung: diffuse ZEB1 expression predicts poor survival. Lung Cancer. 2014; 87(1):39-44. DOI: 10.1016/j.lungcan.2014.11.007. View

11.

Sayan A . Tumour-promoting role of EMT-inducing transcription factor ZEB1 in mantle cell lymphoma. Cell Death Differ. 2014; 21(2):194-5. PMC: 3890963. DOI: 10.1038/cdd.2013.178. View

12.

Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A . The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res. 2008; 68(2):537-44. DOI: 10.1158/0008-5472.CAN-07-5682. View

13.

Zhang P, Sun Y, Ma L . ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015; 14(4):481-7. PMC: 4614883. DOI: 10.1080/15384101.2015.1006048. View

14.

Cho K, Shih I . Ovarian cancer. Annu Rev Pathol. 2008; 4:287-313. PMC: 2679364. DOI: 10.1146/annurev.pathol.4.110807.092246. View

15.

Wellner U, Brabletz T, Keck T . ZEB1 in Pancreatic Cancer. Cancers (Basel). 2013; 2(3):1617-28. PMC: 3837326. DOI: 10.3390/cancers2031617. View

16.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

17.

Feng G, Wang X, Cao X, Shen L, Zhu J . ZEB1 expression in endometrial biopsy predicts lymph node metastases in patient with endometrial cancer. Dis Markers. 2014; 2014:680361. PMC: 4269209. DOI: 10.1155/2014/680361. View

18.

Zivanovic O, Sima C, Iasonos A, Hoskins W, Pingle P, Leitao Jr M . The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol. 2009; 116(3):351-7. PMC: 4843127. DOI: 10.1016/j.ygyno.2009.11.022. View

19.

Quan Y, Jin R, Huang A, Zhao H, Feng B, Zang L . Downregulation of GRHL2 inhibits the proliferation of colorectal cancer cells by targeting ZEB1. Cancer Biol Ther. 2014; 15(7):878-87. PMC: 4100988. DOI: 10.4161/cbt.28877. View

20.

Huang R, Wu D, Yuan Y, Li X, Holm R, Trope C . CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients. PLoS One. 2014; 9(11):e112209. PMC: 4224427. DOI: 10.1371/journal.pone.0112209. View